US OptionsDetailed Quotes

PFE250425P16500

Watchlist

0.00
0.000.00%

15min DelayClose Apr 25 09:30 ET

0.00High0.00Low

Pfizer Stock Discussion

Teddy123

6 hours ago

Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

$Pfizer (PFE.US)$
Breakthrough: Pfizer's New Bladder Cancer Treatment First Major Advance in 30 Years - See 91% Success Rate

Deep Sea

6 hours ago

$Pfizer (PFE.US)$
Pfizer (PFE) announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody, in combination with standard of care Bacillus Calmette-Guerin as induction therapy with or without maintenance in patients with BCG-naive, high-risk non-muscle invasive bladder cancer, NMIBC. The trial met its primary endpoint of event-free survival, EFS, by investigator assessment, demonstrating a clinically meaningful and statistically significan...

搞经济抄底加仓

Yesterday 06:31

I'm just thinking if FDA, WHO, and them are together in this.. ? whatever cancer cure and other cure forever stop at 50% to 85% and they will change to another new treatment and then 50% to 85% and repeat.. seriously, is 2025 already they think we're still living in 1925 when all people don't go to school?
get done once, just once a 100%
$Johnson & Johnson (JNJ.US)$
$Pfizer (PFE.US)$
$E-mini NASDAQ 100 Futures(JUN5) (NQmain.US)$
$E-mini S&P 500 Futures(JUN5) (ESmain.US)$